The impact of the reclusion on patients with blepharospasm during the COVID19 pandemic.
Blepharospasm
Botulinum toxin
Covid-19 lock-down
Focal dystonia
Journal
Clinical neurology and neurosurgery
ISSN: 1872-6968
Titre abrégé: Clin Neurol Neurosurg
Pays: Netherlands
ID NLM: 7502039
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
26
02
2022
revised:
11
06
2022
accepted:
08
07
2022
pubmed:
31
7
2022
medline:
5
10
2022
entrez:
30
7
2022
Statut:
ppublish
Résumé
Blepharospasm (BS) is a focal dystonia that can be treated successfully with Botulinum toxin (BoNT). During the reclusion due to the Covid 19 pandemic many patients missed the scheduled treatment. Aim of the study is to evaluate Level of Disability (LoD) related to BS during the lockdown period. LoD was assessed by an adapted version of Blepharospasm Disability Index (4iBSDI) during reclusion (T1), and three months after the first injection following the lock down phase (T2). 4iBSDI scores were compared between T1 and T2, a correlation between the change of LoD in the two periods (t-delta) and patients' clinical data was analyzed. LoD was not modified between the two periods in most of the patients and it was reduced at T1 in almost one third of the participants. No correlation between t-delta and clinical data was found. LoD did not increase during the lock down period in most of BS patients although BoNT treatment was suspended. Environmental and psychosocial factors may contribute to determine the LoD due to BS.
Sections du résumé
BACKGROUND
Blepharospasm (BS) is a focal dystonia that can be treated successfully with Botulinum toxin (BoNT). During the reclusion due to the Covid 19 pandemic many patients missed the scheduled treatment.
OBJECTIVES
Aim of the study is to evaluate Level of Disability (LoD) related to BS during the lockdown period.
METHODS
LoD was assessed by an adapted version of Blepharospasm Disability Index (4iBSDI) during reclusion (T1), and three months after the first injection following the lock down phase (T2). 4iBSDI scores were compared between T1 and T2, a correlation between the change of LoD in the two periods (t-delta) and patients' clinical data was analyzed.
RESULTS
LoD was not modified between the two periods in most of the patients and it was reduced at T1 in almost one third of the participants. No correlation between t-delta and clinical data was found.
CONCLUSIONS
LoD did not increase during the lock down period in most of BS patients although BoNT treatment was suspended. Environmental and psychosocial factors may contribute to determine the LoD due to BS.
Identifiants
pubmed: 35907350
pii: S0303-8467(22)00244-X
doi: 10.1016/j.clineuro.2022.107363
pmc: PMC9270186
pii:
doi:
Substances chimiques
Neuromuscular Agents
0
Botulinum Toxins, Type A
EC 3.4.24.69
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107363Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Mov Disord. 2009 Feb 15;24(3):407-13
pubmed: 19053054
J Neurol Neurosurg Psychiatry. 1976 Dec;39(12):1204-9
pubmed: 1011031
Mov Disord. 2010 Mar 15;25(4):459-65
pubmed: 20108377
Neurol Sci. 2014 Mar;35(3):397-400
pubmed: 23949734
Parkinsonism Relat Disord. 2021 Oct;91:109-114
pubmed: 34583301
Gen Hosp Psychiatry. 2011 Sep-Oct;33(5):476-81
pubmed: 21762995
Neurology. 2013 Jul 16;81(3):236-40
pubmed: 23771487
Sci Rep. 2021 Sep 8;11(1):17856
pubmed: 34497334
Mov Disord. 2017 Apr;32(4):498-509
pubmed: 28186662
Mov Disord Clin Pract. 2014 Dec 1;1(4):280-284
pubmed: 25485288
J Neural Transm (Vienna). 2021 Apr;128(4):549-558
pubmed: 33099684
Arq Neuropsiquiatr. 2005 Jun;63(2A):213-6
pubmed: 16100964
J Clin Neurosci. 2020 Apr;74:130-134
pubmed: 32067829
J Neuroophthalmol. 2007 Dec;27(4):275-80
pubmed: 18090560
Parkinsonism Relat Disord. 2019 Sep;66:51-55
pubmed: 31279634
Eur Neurol. 2002;47(3):161-4
pubmed: 11914554
Int J Psychiatry Clin Pract. 2021 Nov;25(4):344-349
pubmed: 32669012